https://orcid.org/0000-0002-9383-5722
Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Aliki I. Venetsanopoulou, Paraskevi V. Voulgari & Alexandros A. Drosos. (2022) Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. Expert Review of Clinical Immunology 18:5, pages 485-493.
Read now
Read now
Eleftherios Pelechas, Paraskevi V Voulgari & Alexandros A. Drosos. (2021) Preclinical discovery and development of adalimumab for the treatment of rheumatoid arthritis. Expert Opinion on Drug Discovery 16:3, pages 227-234.
Read now
Read now
Yun Zeng, Jie Huang, Chang Cui, Shuang Yang, Ze-Yu Zhang, Saqib Ali, Zhi-Jun Huang & Guo-Ping Yang. (2021) QL0902, a proposed etanercept biosimilar: pharmacokinetic and immunogenicity profile to its reference product in healthy Chinese male subjects. Expert Opinion on Biological Therapy 21:1, pages 105-110.
Read now
Read now
Yeong Wook Song, Yong-Beom Park & Jinseok Kim. (2021) LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 21:1, pages 1-8.
Read now
Read now
Eleftherios Pelechas, Paraskevi V Voulgari & Alexandros A Drosos. (2020) Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis. Expert Opinion on Pharmacotherapy 21:17, pages 2153-2160.
Read now
Read now
Eleftherios Pelechas, Paraskevi V Voulgari & Alexandros A Drosos. (2019) Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis. Therapeutics and Clinical Risk Management 15, pages 1073-1079.
Read now
Read now
Articles from other publishers (15)
Héctor Corominas, David Young, J. R. Fraser Cummings, Yoram Bouhnik, Alessandro Armuzzi, Diamant Thaci & Jihyun Kim. (2023) Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review. Clinical Drug Investigation 43:8, pages 579-593.
Crossref
Crossref
Sara Tenti, Olivier Bruyère, Sara Cheleschi, Jean-Yves Reginster, Nicola Veronese & Antonella Fioravanti. (2023) An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis. Therapeutic Advances in Musculoskeletal Disease 15, pages 1759720X2311586.
Crossref
Crossref
Wan-Hee Yoo, Young Mo Kang, Dong Wook Kim, Eun Ha Kang, Yeon-Ah Lee, Chang-Hee Suh, Yoon-Kyoung Sung, Sang-Hoon Lee, Dong-Ha Gu, Jiwon Lee & Jung-Yoon Choe. (2022) Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data. Rheumatology and Therapy.
Crossref
Crossref
Ruijuan Guan, Liang Yuan, Jingpei Li, Jian Wang, Ziying Li, Zhou Cai, Hua Guo, Yaowei Fang, Ran Lin, Wei Liu, Lan Wang, Qiuyu Zheng, Jingyi Xu, You Zhou, Jing Qian, Mingjing Ding, Jieping Luo, Yuanyuan Li, Kai Yang, Dejun Sun, Hongwei Yao, Jianxing He & Wenju Lu. (2022) Bone morphogenetic protein 4 inhibits pulmonary fibrosis by modulating cellular senescence and mitophagy in lung fibroblasts. European Respiratory Journal 60:6, pages 2102307.
Crossref
Crossref
Haixia Zhu, Hongxiang Wang, Yin Cheng, Dongyue Liu, Aizhen Zhang, Zongzhuang Wen & Jiangang Gao. (2022)
Hadh
deficiency induced oligoasthenoteratozoospermia through the
TNF
‐α/Bcl‐2 pathway in male mice
. The FASEB Journal 36:12.
Crossref
Crossref
Thomas G. Biel, Talia Faison, Alicia M. Matthews, Guozhang Zou, Uriel Ortega-Rodriguez, Melissa A. Pegues, Nicole Azer, Fabiola Gomez, Sarah Johnson, Sarah Rogstad, Kang Chen, Hang Xie, Cyrus Agarabi, V. Ashutosh Rao & Tongzhong Ju. (2022) An etanercept O-glycovariant with enhanced potency. Molecular Therapy - Methods & Clinical Development 25, pages 124-135.
Crossref
Crossref
Win Min Oo & David J. Hunter. (2022) Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs). Therapeutic Advances in Musculoskeletal Disease 14, pages 1759720X2210902.
Crossref
Crossref
Hong Wu, Qingxia You, Yi Jiang & Fangxiang Mu. (2021) Tumor necrosis factor inhibitors as therapeutic agents for recurrent spontaneous abortion (Review). Molecular Medicine Reports 24:6.
Crossref
Crossref
Eleftherios Pelechas, Alexandra Papoudou-Bai, Paraskevi V. Voulgari & Alexandros A. Drosos. (2021) Cutaneous Autoimmune Phenomena of the Anti-TNFa Biosimilars. Casebased Review. Current Rheumatology Reviews 17:2, pages 267-270.
Crossref
Crossref
Ioana Gherghescu & M. Begoña Delgado-Charro. (2020) The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA. Pharmaceutics 13:1, pages 48.
Crossref
Crossref
Mihail Virgil Boldeanu, Adrian Răzvan Ionescu, Valeriu Horațiu Popoviciu, Andreea Lili Bărbulescu, Ștefan Cristian Dinescu, Isabela Siloși, Maria Forțofoiu, Rodica Pădureanu, Andreea Meca, Vlad Pădureanu, Mircea Cătălin Forțofoiu, Ioan Sabin Poenariu, Lidia Boldeanu & Ananu Florentin Vreju. 2020. Rheumatoid Arthritis - Other Perspectives towards a Better Practice. Rheumatoid Arthritis - Other Perspectives towards a Better Practice.
Pelechas Eleftherios & Karagianni Panagiota. (2020) Rheumatoid arthritis: Treatment evolution over the years. Open Journal of Pharmacology and Pharmacotherapeutics 5:1, pages 024-026.
Crossref
Crossref
Cătălin Codreanu, Claudiu C. Popescu, Corina Mogoșan, Luminița Enache, Sânziana Daia, Ruxandra Ionescu & Daniela Opriș-Belinski. (2019) Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis – A comparison in a real-world national cohort. Biologicals 62, pages 27-32.
Crossref
Crossref
Alexandros A. Drosos, Eleftherios Pelechas & Paraskevi V. Voulgari. (2019) Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?. Journal of Clinical Medicine 8:8, pages 1237.
Crossref
Crossref
Eleftherios Pelechas, Paraskevi Voulgari & Alexandros Drosos. (2019) Golimumab for Rheumatoid Arthritis. Journal of Clinical Medicine 8:3, pages 387.
Crossref
Crossref